HSJ
 
Financial value and value to patients: balancing the equation

Live webinar: Thursday 8 September 2016, 10.30am GMT

Dear Colleague,

The need to make difficult decisions over which treatments and services to fund permeates the NHS. In few areas is the problem as acute as in anti-cancer therapy. New medicines are regularly coming onto the market which have the potential to extend the lives of patients with late stage disease.


Assessing the value of such medicines is complex – a matter of balancing benefit to the patient with financial cost, at a time when the medicine is so new information on efficacy may be limited.


HSJ, in association with Roche, is running a free webinar to discuss how we can best make difficult decisions about patient value and financial cost.


Questions for discussion are likely to include:

  • How can we best assess the value of new medicines? 
  • How can we ensure patients have equal, speedy access to innovative treatments across the UK?
  • Have the concerns that led to the creation of the Cancer Drugs Fund in 2009 been addressed?
  • How might the changes recently made to the Cancer Drugs Fund affect access to treatments?

The webinar is a non-promotional meeting to discuss anti-cancer medicines – there is no intention to discuss the funding of individual medicines, including Roche medicines.

Already confirmed to speak is Mark Flannagan, chief executive of Beating Bowel Cancer, with other high profile names to follow. The debate will be chaired by HSJ correspondent Will Hazell.

Confirmed speakers

Mark Flannagan, chief executive, Beating Bowel Cancer

Mark joined Beating Bowel Cancer in July 2010 from the Royal College of General Practitioners, where he was director of policy and communications. He has previously held senior and board level positions in organisations including Diabetes UK, the BBC, and homelessness charity Crisis.


Will Hazell, correspondent, (webinar chair) HSJ

Will is a correspondent for HSJ, reporting on regulation, quality, specialised services and the South West. In 2015 he won the Medical Journalists’ Association young journalist of the year award.

Richard Erwin, general manager, Roche Products Ltd
Richard has been general manager of Roche in the UK since September 2015. He joined the firm in 1996, working initially in UK sales and marketing before moving into European and global leadership roles. Before taking up his current role, he spent two years as general manager in Belgium/Luxembourg, working with clinicians and the health service to overcome some of the key challenges in making sure patients have the medicines they need.


Make sure you don't miss out on this vital debate, register now.


We look forward to welcoming you to this webinar and to HSJ TV.


Yours sincerely,

Alastair McLellan
Editor, HSJ

P.S. If you are not free to watch the live broadcast, you can view a recording at a later date. Please register to ensure you have access.



Job bag number: RXUKCOMM01567c

Date of preparation: August 2016

In association with

Speakers
Mark Flannagan Mark Flannagan
chief executive
Beating Bowel Cancer
Will Hazell Will Hazell
correspondent
HSJ
Richard Erwin Richard Erwin
general manager
Roche Products Ltd
 
Facebook
Twitter
Google+
.